Literature DB >> 31653787

Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species.

Andre Franke1, Corinna Bang2, Malte Christoph Rühlemann1, Miriam Emmy Leni Solovjeva1, Roman Zenouzi3, Timur Liwinski3, Martin Kummen4,5, Wolfgang Lieb6, Johannes Roksund Hov4,5, Christoph Schramm3,7.   

Abstract

Entities:  

Keywords:  mycobiome; primary sclerosing cholangitis

Mesh:

Year:  2019        PMID: 31653787      PMCID: PMC7497579          DOI: 10.1136/gutjnl-2019-320008

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.

Letter to the editor

We read with interest the recent Gut article by Lemoinne et al describing a dysbiosis of the fungal gut community in faeces of patients suffering from primary sclerosing cholangitis (PSC).1 Though several reports, including our own previous data, support a functional and potentially pathogenic link between the intestinal bacteriota and liver inflammation in PSC,2 3 the aetiology of the disease remains largely unknown. We here report on the fungal mycobiome results of our cohort from Northern Germany approved by the local ethics committees (A148/14 and MC-111/15) comprising stool samples of 66 healthy control (HC) subjects, 65 patients with well-characterised PSC (including a subgroup with concomitant colitis (PSC-IBD), n=32) and 38 subjects with UC.3 PCR and sequencing of the fungus-specific internal transcribed spacer 2 genomic region was performed as previously described4 using the primer pair 5.8S-Fun and ITS4-Fun on an Illumina MiSeq machine. Sequencing data were subjected to quality control by using the open source package DADA2 (V.1.10)5 in R (V.3.5.1; https://github.com/mruehlemann/ikmb_amplicon_processing). Amplicon sequence variants were taxonomically annotated using the UNITE ITS database (V.7.2).6 In disagreement with the findings in the French cohort,1 overall fungal alpha diversity in the German cohort was neither altered in PSC nor in UC versus HC as calculated by Shannon species equivalent (figure 1A). None of the disease groups significantly deviated in community composition from healthy individuals (all padonis >0.05; figure 1B). Fungal composition on phylum level was found to be mainly dominated by Ascomycota (figure 1C), particularly by the genera Saccharomyces, Candida and Dipodascus (figure 1D) in relatively higher abundance of reads when compared with the findings of Lemoinne et al.1 Though our results generally validate the previously described overall fungal composition in stool, we were not able to detect the genus Exophiala, which was found in five PSC patients from France exclusively. Whether this is due to methodological differences (choice of primer sets, data analysis tools and sampling depth) or presence of this fungus in only a subset of PSC patients not sampled in the German cohort needs to be determined.
Figure 1

Mycobiome of individuals with primary sclerosing cholangitis (PSC) and UC as well as healthy controls (HC) (all of northern German origin). Rarefaction curves for Shannon diversity of sequence variants reached plateau between 50 and 100 sequences per samples, thus samples were normalised to 100 random reads per sample. (A) Alpha diversity as presented by Shannon species equivalents (all p>0.05). (B) Beta diversity ordination of the Bray-Curtis dissimilarity based on genus-level fungal abundances (all padonis >0.05). (C) Phylum-level and (D) genus-level mean abundances of all taxa with >1% mean abundance and present in at least 10 samples. (E) Group-wise box-and-whisker plots for significant genus level annotations tested for differential abundances with individual values represented as data points. (F) Differences in group-mean abundances of patients with PSC and UC, as compared with HC. *q<0.05, **q<0.01.

Mycobiome of individuals with primary sclerosing cholangitis (PSC) and UC as well as healthy controls (HC) (all of northern German origin). Rarefaction curves for Shannon diversity of sequence variants reached plateau between 50 and 100 sequences per samples, thus samples were normalised to 100 random reads per sample. (A) Alpha diversity as presented by Shannon species equivalents (all p>0.05). (B) Beta diversity ordination of the Bray-Curtis dissimilarity based on genus-level fungal abundances (all padonis >0.05). (C) Phylum-level and (D) genus-level mean abundances of all taxa with >1% mean abundance and present in at least 10 samples. (E) Group-wise box-and-whisker plots for significant genus level annotations tested for differential abundances with individual values represented as data points. (F) Differences in group-mean abundances of patients with PSC and UC, as compared with HC. *q<0.05, **q<0.01. Disease-associated differential abundance of fungal taxa was investigated by applying Student’s t-test to the arcsin-squareroot-transformed relative abundances of all genera with mean abundance >1% and present in at least 10 individuals. This analysis revealed increased levels of the genera Candida and Humicola (species level annotation suggests H. grisea) in PSC patients with and without concomitant colitis compared with HC (all qBH <0.05; figure 1E and F) and UC (all qBH <0.1; figure 1E) individuals. H. grisea, recently reclassified as Trichocladium griseum,7 belongs to the fungal class Sordariomycetes, thus our results reproduce the significant increase of this class in PSC patients, as previously described by Lemoinne and colleagues, but at increased taxonomic resolution. Previous research on T. griseum showed that it is most frequently isolated from soil and plants but also occasionally found in patients suffering from peritonitis.8 In addition, the validated increase of Candida species in PSC patients argues for an immunogenic role of these fungi, particularly with respect to earlier findings that demonstrated their high potential to induce Th17 response in T cells.9 Increased Th17 numbers have previously been reported in PSC patients and recently been shown to be involved in PSC pathogenesis.10 In summary, both the significant increase of the fungal class Sordariomycetes, likely T. griseum, as well as of Candida species in stool samples of PSC patients, now found in two independent and geographically distinct PSC patient panels that were analysed with divergent methodological approaches, strongly demands for additional analyses on these fungi and their role in PSC.
  10 in total

1.  Humicola sp. as a Cause of Peritoneal Dialysis-Associated Peritonitis.

Authors:  Nathan Burns; Ian Arthur; Michael Leung; Selva Ketharanathan; Marcelo Sandoval-Denis; Josepa Gené; Josep Guarro; Aron Chakera
Journal:  J Clin Microbiol       Date:  2015-07-08       Impact factor: 5.948

2.  Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.

Authors:  Nobuhiro Nakamoto; Nobuo Sasaki; Ryo Aoki; Kentaro Miyamoto; Wataru Suda; Toshiaki Teratani; Takahiro Suzuki; Yuzo Koda; Po-Sung Chu; Nobuhito Taniki; Akihiro Yamaguchi; Mitsuhiro Kanamori; Nobuhiko Kamada; Masahira Hattori; Hiroshi Ashida; Michiie Sakamoto; Koji Atarashi; Seiko Narushima; Akihiko Yoshimura; Kenya Honda; Toshiro Sato; Takanori Kanai
Journal:  Nat Microbiol       Date:  2019-01-14       Impact factor: 17.745

3.  Redefining Humicola sensu stricto and related genera in the Chaetomiaceae.

Authors:  X W Wang; F Y Yang; M Meijer; B Kraak; B D Sun; Y L Jiang; Y M Wu; F Y Bai; K A Seifert; P W Crous; R A Samson; J Houbraken
Journal:  Stud Mycol       Date:  2018-08-07       Impact factor: 16.097

4.  Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.

Authors:  Sara Lemoinne; Astrid Kemgang; Karima Ben Belkacem; Marjolène Straube; Sarah Jegou; Christophe Corpechot; Olivier Chazouillères; Chantal Housset; Harry Sokol
Journal:  Gut       Date:  2019-04-19       Impact factor: 23.059

5.  The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.

Authors:  Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov
Journal:  Gut       Date:  2016-02-17       Impact factor: 23.059

6.  Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis.

Authors:  Janosch Katt; Dorothee Schwinge; Tanja Schoknecht; Alexander Quaas; Ingo Sobottka; Eike Burandt; Christoph Becker; Markus F Neurath; Ansgar W Lohse; Johannes Herkel; Christoph Schramm
Journal:  Hepatology       Date:  2013-07-30       Impact factor: 17.425

7.  DADA2: High-resolution sample inference from Illumina amplicon data.

Authors:  Benjamin J Callahan; Paul J McMurdie; Michael J Rosen; Andrew W Han; Amy Jo A Johnson; Susan P Holmes
Journal:  Nat Methods       Date:  2016-05-23       Impact factor: 28.547

8.  Accurate Estimation of Fungal Diversity and Abundance through Improved Lineage-Specific Primers Optimized for Illumina Amplicon Sequencing.

Authors:  D Lee Taylor; William A Walters; Niall J Lennon; James Bochicchio; Andrew Krohn; J Gregory Caporaso; Taina Pennanen
Journal:  Appl Environ Microbiol       Date:  2016-11-21       Impact factor: 4.792

9.  The UNITE database for molecular identification of fungi: handling dark taxa and parallel taxonomic classifications.

Authors:  Rolf Henrik Nilsson; Karl-Henrik Larsson; Andy F S Taylor; Johan Bengtsson-Palme; Thomas S Jeppesen; Dmitry Schigel; Peter Kennedy; Kathryn Picard; Frank Oliver Glöckner; Leho Tedersoo; Irja Saar; Urmas Kõljalg; Kessy Abarenkov
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis.

Authors:  Malte Rühlemann; Timur Liwinski; Femke-Anouska Heinsen; Corinna Bang; Roman Zenouzi; Martin Kummen; Louise Thingholm; Marie Tempel; Wolfgang Lieb; Tom Karlsen; Ansgar Lohse; Johannes Hov; Gerald Denk; Frank Lammert; Marcin Krawczyk; Christoph Schramm; Andre Franke
Journal:  Aliment Pharmacol Ther       Date:  2019-06-28       Impact factor: 8.171

  10 in total
  5 in total

Review 1.  Roles for the mycobiome in liver disease.

Authors:  Suling Zeng; Bernd Schnabl
Journal:  Liver Int       Date:  2022-01-17       Impact factor: 5.828

Review 2.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

Review 3.  Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver-Gut Axis.

Authors:  Niklas Grüner; Jochen Mattner
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

4.  Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant - a pilot study.

Authors:  Thijmen Visseren; Gwenny Manel Fuhler; Nicole Stephanie Erler; Yoena Roos Anna Nossent; Herold Johnny Metselaar; Jan Nicolaas Maria IJzermans; Sarwa Darwish Murad; Maikel Petrus Peppelenbosch
Journal:  Transpl Int       Date:  2020-07-26       Impact factor: 3.782

Review 5.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.